Article view: 472

Article download: 182

International Journal of Pharmaceutical Chemistry and Analysis

Ramucirumab – A new hope for colorectal cancer patient

Full Text PDF Share on Facebook Share on Twitter

Author Details : Shikha Sharma, Sandeep Sharma, Rahul Kalotra, DN Prasad

Volume : 3, Issue : 4, Year : 2016

Article Page : 183-192

Suggest article by email


Metastatic colorectal cancer remains one of the deadliest types of cancer having significant presence globally. Exhaustive research throughout the scientific fraternities worldwide is now getting focused on selectively targeting the cancer cells. One such achievement has been the recent approval of ramucirumab by USFDA which has added to the existing armamentarium of angiogenesis inhibitors. Ramucirumab is a fully humanized monoclonal antibody directed against the extracellular domain of vascular endothelial growth factor receptor 2 (VEGFR-2) which selectively inhibits the human VEGFR-2 with a much greater affinity than its natural ligands and can be used in the second-line treatment of metastatic colorectal cancer. The current review focuses on the details regarding ramucirumab, its journey from preclinical trial to clinical trial and the way forward.

Colorectal Cancer, Monoclonal antibody, Vascular endothelial growth factor receptor 2, Ramucirumab

How to cite : Sharma S, Sharma S, Kalotra R, Prasad D, Ramucirumab – A new hope for colorectal cancer patient. Int J Pharm Chem Anal 2016;3(4):183-192

Copyright © 2016 by author(s) and Int J Pharm Chem Anal. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (